BioCryst Pharmaceuticals | BCRX - Selling And Administration Expenses


BioCryst Pharmaceuticals reported $95.78M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Chugai Pharma JPY 28.9B 8.02B Mar/2026
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
DBV Technologies USD 3.63M 3.18M Sep/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novavax USD 25.53M 1.34M Dec/2025
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026